Harmony Biosciences Will Present New Sleep Drug Data
New clinical trial results for a narcolepsy and hypersomnia treatment will be presented to medical researchers.
Updated on Oct. 1, 2026 in Sleep Disorders
Harmony Biosciences will present findings from its Phase 3 trials for HBS-301 at the 17th European Narcolepsy Days in Bern, Switzerland. These upcoming poster presentations will share data regarding the medication for the treatment of excessive daytime sleepiness.
Why it matters
Understanding new developments in treatments for sleep disorders like narcolepsy and idiopathic hypersomnia is critical for patients managing chronic daytime sleepiness. This data release provides insight into the progress of therapies designed to improve wakefulness.
The upcoming presentation details Phase 3 clinical trial results from the ONSTRIDE-1 narcolepsy study and the ONSTRIDE-2 idiopathic hypersomnia study. These trials evaluate HBS-301, an enteric-coated pitolisant tablet with strengths up to 60 mg.
The players
Harmony Biosciences
A pharmaceutical company established in 2017 and headquartered in Plymouth Meeting, Pennsylvania, that specializes in developing therapies for rare neurological diseases and sleep disorders.
The details
HBS-301 is being developed as an enteric-coated formulation of pitolisant, a medication that acts as a selective histamine H3 receptor antagonist and inverse agonist. By targeting these receptors in the brain, the treatment is designed to enhance the release of histamine to promote wakefulness and combat excessive daytime sleepiness. The studies aim to establish the efficacy of this delivery method in patients with diagnosed sleep disorders.
Timeline
October 2, 2026, 16:30 CEST
October 3, 2026, 12:30 CEST
Health Landscape
The development of enteric-coated HBS-301 reflects an ongoing effort in sleep medicine to optimize delivery mechanisms for established treatments. This trial data contributes to the broader clinical progression of histamine-targeted therapies for sleep-wake disorders.
Patients dealing with excessive daytime sleepiness should monitor updates on new treatment formulations as clinical trial results become public. It is important to discuss any changes to treatment options or new medication availability with your physician to understand how they may apply to your care.
The takeaway
Ongoing clinical trials for new medication formulations are vital for expanding the range of treatment options available for sleep disorders. Patients should stay informed about emerging study findings and consult their doctor regarding how new data might influence their long-term management plan.
What happens next
Harmony Biosciences will present trial data for HBS-301 on October 2, 2026, at 16:30 CEST and again on October 3, 2026, at 12:30 CEST.
Further reading
For more information on the current state of treatment research, visit our Sleep Disorders section.
